Clinical trial
Postoperative Concurrent Chemoradiotherapy Combined With Recombinant Human Endostatin for High-risk Early Stage Cervical Cancer: A Phase II Pilot Study (ChESS).
NCT03622827 is registered in ClinicalTrials.gov with Nanjing Medical University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Postoperative Concurrent Chemoradiotherapy Combined With Recombinant Human Endostatin for High-risk Early Stage Cervical Cancer: A Phase II Pilot Study (ChESS).
- Lead sponsor
- Nanjing Medical University
- Phase
- Phase 2
- Overall status
- Unknown status
- Start date
- July 31, 2018
- Completion date
- July 30, 2025
- Enrollment
- 120 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.